Literature DB >> 11086182

P53 overexpression in bone marrow biopsies in refractory anemia and aplastic anemia: impact of antibody selection.

M T Elghetany1.   

Abstract

There is a growing interest in studying cell cycle and apoptosis in the myelodysplastic syndromes (MDS). p53 has been a major target of several studies. We examined the impact of antibody selection on p53 overexpression in bone marrow (BM) biopsies of 28 patients with refractory anemia (RA) in addition to 10 cases of aplastic anemia (AA) using three antibodies DO-7, PAb 1801, and PAb 240. DO-7 was positive in 68%, PAb 1801 in 18% and PAb240 in 4% of RA patients. All three antibodies were negative in AA. We conclude that antibody selection is an important variable in studying p53 in MDS regardless of the method of fixation or decalcification of BM trephine biopsies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11086182     DOI: 10.1016/s0145-2126(00)00062-x

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  F-blast is a useful marker for differentiating hypocellular refractory anemia from aplastic anemia.

Authors:  Jong Weon Choi; Masahiko Fujino; Masafumi Ito
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

2.  CD34 and p53 immunohistochemical stains differentiate hypocellular myelodysplastic syndrome (hMDS) from aplastic anemia and a CD34 immunohistochemical stain provides useful survival information for hMDS.

Authors:  Choong-Hwan Cha; Chan-Jeoung Park; Hyun-Sook Chi; Eul Ju Seo; Seongsoo Jang; Young-Uk Cho; Kyoo-Hyung Lee; Je-Hwan Lee; Jung-Hee Lee; Ho Joon Im; Jong-Jin Seo
Journal:  Ann Lab Med       Date:  2014-10-28       Impact factor: 3.464

3.  Intra Q-body: an antibody-based fluorogenic probe for intracellular proteins that allows live cell imaging and sorting.

Authors:  Yancen Dai; Yuko Sato; Bo Zhu; Tetsuya Kitaguchi; Hiroshi Kimura; Farid J Ghadessy; Hiroshi Ueda
Journal:  Chem Sci       Date:  2022-08-01       Impact factor: 9.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.